Abstract
We evaluated the effects of 22-oxa-1α, 25-dihydroxyvitamin D3 (OCT) on the inhibition of growth, the induction of differentiation, and the production of cytokines in human myeloid leukemia (HL-60) cells. While 1α, 25-dihydroxyvitamin D3 (1, 25 (OH) 2D3) induces differentiation and inhibits proliferation of HL-60 cells, it has been found to induce hypercalcemia in clinical trials. However, OCT does not induce hypercalcemia and induces differentiation with a potency similar to that of 1, 25 (OH) 2D3. In the present study OCT significantly more strongly inhibited cell proliferation and more effectively induced cytokine production than did 1, 25 (OH) 2D3. OCT thus appears to be a promising candidate for treating myeloid leukemia and myelo-dysplastic syndromes.
